Overview

Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
26 patients presenting a rhegmatogenous retinal detachment with more than 4 days of duration will be prospectively included. A single dose of ursodeoxycholic acid will be administered orally before surgery at different time-points in 22 subjects. Standard surgery will be performed and ocular samples will be collected during the procedure. Ursodeoxycholic acid treatment will be continued in treated patients during 3 months after surgery. Ocular and serum samples from the 4 untreated patients will serve as negative controls for the determination of UDCA levels.
Phase:
Phase 1
Details
Lead Sponsor:
Francine Behar-Cohen
Collaborators:
Emory University
University of Lausanne Hospitals
Treatments:
Ursodeoxycholic Acid